Details for Patent: 10,034,877

Which drugs does patent 10,034,877 protect, and when does it expire?

Patent 10,034,877 protects TRADJENTA and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: 10,034,877

Title:	Treatment for diabetes in patients inappropriate for metformin therapy
Abstract:	The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
Inventor(s):	Dugi; Klaus (London, GB), Graefe-Mody; Eva Ulrike (Ingelheim am Rhein, DE), Harper; Ruth (Reading, GB), Woerle; Hans-Juergen (Munich, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	15/287,228
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,034,877
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,034,877

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes						TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT

International Family Members for US Patent 10,034,877

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072920
Australia	2009279085
Brazil	PI0916997